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Abstract 
We have recently reported that the outcome of acute myeloid leukemia (AML) patients 
with t(6;9)(p23;q34) who underwent allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) was comparable to that of patients with a normal karyotype. We performed 
a further analysis regarding the prognostic factors for t(6;9)(p23;q34) AML patients 
who underwent a HSCT. Seven pediatric patients and 57 adult patients, transplanted 
between 1996 and 2007, were assessed in this study. The overall survival (OS) of the 
pediatric patients tended to be better than the OS of the adults, although there were no 
statistically significant differences. The present study focused on the adult patients 
revealed that the disease status at HSCT was the sole prognostic factor affecting the OS 
identified in the univariate analysis. A multivariate analysis showed that the disease 
status at HSCT and M2 in the FAB classification were extracted as the significant 
variables affecting the OS. The patients who were not in remission at HSCT and had 
non-FAB-M2 showed a poorer outcome; 6 deaths in the 9 patients were due to a relapse 
of the AML. These findings suggest that novel therapeutic approaches might be needed 
for patients with these poor prognostic factors. 
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Introduction 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often selected as a 
curative treatment strategy for acute myeloid leukemia (AML). In particular, AML 
patients with poor cytogenetics at diagnosis are considered for allo-HSCT as the 
first-line therapy.(1-4) Recently, we have reported that AML with the t(6;9)(p23;q34) 
abnormality, which predicts a very poor prognosis in patients treated with 
chemotherapy,(5) is associated with an outcome in patients receiving allo-HSCT that is 
comparable to that in patients with a normal karyotype.(6) However, 55% of the AML 
patients with t(6;9)(p23;q34) eventually had a negative outcome. We herein performed a 
further analysis for AML patients with t(6;9)(p23;q34) who received allo-HSCT to 
identify the prognostic factors affecting their overall survival (OS). 
 
Materials and Methods 
Study population and data management 
A total of 64 de novo AML patients with t(6;9)(p23;q34) detected in G-band staining at 
diagnosis, who received their first allo-HSCT between January 1996 and December 
2007, were extracted from the databases of the Japan Society for Hematopoietic Cell 
Transplantation (JSHCT) and the Japan Cord Blood Bank Network. The cytogenetic 
data were analyzed according to the Southwestern Oncology Group (SWOG) criteria for 
each institution, instead of by central review.(3) The clinical data were collected using a 
standardized report form, which was submitted at 100 days, 1 year and annually after 
HSCT. This study was approved by the Committee for Nationwide Survey Data 
Management of the JSHCT. Written informed consent was obtained in accordance with 
the Declaration of Helsinki. 
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Statistical analysis 
The OS was defined as the number of days from HSCT until death from any cause. 
Non-relapse mortality (NRM) was defined as death without relapse. Any patients who 
were alive at the last-follow-up date were censored. The analysis was performed using 
the R version 2.13.0 software program (R Foundation for Statistical Computing; 
www.r-project.org).(7) The probability of OS was calculated using the Kaplan-Meier 
method and compared using the log-rank test. The probabilities of TRM and disease 
relapse were compared using the Grey test(8) and were analyzed using the cumulative 
incidence analysis,(7) while considering relapse and death without disease relapse as 
respective competing risks. 
 The following variables related to the survival of the adult patients older than 
15 years and their clinical data were compared in a univariate analysis: recipient 
characteristics (age; younger than 35 vs. older than 35, gender, performance status at 
diagnosis; 0 to 2 vs. 3 or 4, FAB classification; M2 or others, positivity for peroxidase 
in leukemic blasts at diagnosis; less than 50% vs. greater than 50%, cytogenetic 
abnormality), donor characteristics (age; younger than 35 vs. older than 35, gender, sex 
compatibility, compatibility of cytomegalovirus antibody serostatus, relationship; 
related vs. unrelated, and ABO compatibility), transplant characteristics (disease status 
at HSCT; CR vs. non-CR, use of total body irradiation as a preconditioning regimen, 
source of the graft; bone marrow (BM), peripheral blood stem cell (PBSC), cord blood 
(CB)), GVHD prophylaxis; cyclosporine vs. tacrolimus and the use of methotrexate. 
Multivariate Cox models were used to evaluate the hazard ratios associated with the 
prognosis. Covariates found to be significant in the univariate analyses (P ≤ 0.10) were 
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included in the models. For both the univariate and the multivariate analyses, P values 
were two sided, and outcomes were considered to be significant for P ≤ 0.05. 
 
Results 
Survival of the pediatric patients 
A total of 64 AML patients with t(6;9)(p23;q34) patients were analyzed (Table 1). The 
OS of the 7 pediatric patients younger than 14 years old seemed to be better than the OS 
of the 57 adult patients older than 15 years, although there were no statistically 
signficant differences between the groups (Figure 1A, the probability of 3-year OS in 
pediatric patients and adult patients was 83% and 48%, respectively (P=0.12)).  
 
OS, relapse and NRM of the adult patients 
We performed a further analysis in the 57 adult patients older than 15 years. The 
univariate analysis showed that the disease status at HSCT was the sole significant 
prognostic factor affecting the OS (Figure 1B, the probability of 3-year OS in patients 
with CR and with non-CR at HSCT was 69% and 29%, respectively (P<0.003)), and the 
number of HLA disparities, M2 in the FAB classification, and CB as the source of the 
graft were calculated to have a P-value < 0.1 (Table 2). No statistically significant 
tendencies related to gender, gender mismatch between the donor and recipient, 
recipient cytomegalovirus serostatus or the use of total body irradiation for the 
preconditioning regimen were observed. The cumulative incidence of relapse and of 
NRM are shown in Figure 2; the cumulative incidence of relapse was significantly 
lower in patients with a CR at HSCT than in patients without CR (Figure 2A, the 3-year 
cumulative incidence was 25% in CR patients and 58% in non-CR patients (P=0.005)), 
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although such differences were not seen in the cumulative incidence of NRM between 
these 2 groups (Figure 2B, the 3-year cumulative incidence was 10% in CR patients and 
16% in non-CR patients (P=0.85)).  
 In the multivariate analysis, the disease status at HSCT and FAB-M2 remained 
the significant variables associated with the OS (Table 2). The OS of the patients 
categorized by the combination of the disease status at HSCT and FAB-M2 showed a 
favorable outcome in FAB-M2 patients with a CR at HSCT (Figure 3, the probability of 
3-year OS in patients with CR/FAB-M2, CR/non-FAB-M2, non-CR/FAB-M2 and 
non-CR/non-FAB-M2 was 76%, 60%, 43% and not reached, respectively (P<0.001)). In 
contrast, the patients who were not in remission at the time of HSCT and had 
non-FAB-M2 showed a poorer outcome; the cause of death in 6 out of the 9 patients 
was due to a relapse of the AML. 
 
Discussion 
The characteristics of the patients with the t(6;9)(p23;q34) subtype of AML were known 
to have a poor prognosis and to be associated with development at a younger age, 
frequent M2 in the FAB classification, and achievement of a morphological 1st CR not 
predicting a favorable outcome.(9) In this study, we distinguished the 7 pediatric 
patients who seemed to have a superior OS from the adult patients, because the better 
prognosis in the children might reflect differences in the pathogenesis of the disease, 
consistent with the better OS in the previous report.(5) 
 The current study revealed that the cumulative incidence of relapse was 
significantly worse in patients without CR than in patients with CR, although the 
cumulative incidence of NRM was comparable between these two groups. These results 
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suggest that it is important to have an appropriate treatment strategy, ie, allo-HSCT for 
the patients who achieved 1st CR is imperative, while the development of an effective 
treatment for the refractory/relapsed AML patients is critical. 
 The presence of FLT3-ITD is recognized as a poor prognostic factor in AML 
patients.(10-12) Since FLT3-ITD was frequently detected in patients with 
t(6;9)(p23;q34),(5) it has been suggested that the presence of FLT3-ITD might 
contribute to the poor prognosis of the t(6;9)(p23;q34) patients.(13) With regard to the 
rate of FLT3-ITD positive disease, there were no apparent between-group differences in 
the FAB classification,(14) however, the expression levels of FLT3 were higher in 
patients with monocytic AML (M4 and M5 in the FAB classification) than in the other 
patients,(15) and were associated with an unfavorable prognosis.(16) The current study 
has distinguished FAB-M2 from non-M2, and two-thirds of the non-M2 cases (n=23) in 
the present study consisted of monocytic AML (the number of M4 patients and M5 
patients was 13 and 2, respectively). Therefore, the poor prognosis of the non-FAB-M2 
patients might be due to the presence of FLT3-ITD. Unfortunately, we could not 
confirm this hypothesis because this retrospective analysis did not examine the presence 
of FLT3-ITD. Future studies will be needed to determine whether the FLT3-ITD status 
was responsible for the poor prognosis in these patients. 
 In conclusion, the current study showed that a CR at the time of HSCT and M2 
in the FAB classification are favorable prognostic factors in AML patients with 
t(6;9)(p23;q34). However, refractoriness to chemotherapy remains an obstacle to a 
favorable allo-HSCT outcome, especially in non-M2 patients. Novel therapeutic 
approaches, such as immunotherapy using anti-FLT antibodies combined with HSCT, 
may also be required for patients expected to have a poor prognosis.(17, 18) 
 9 / 14 
 
Acknowledgements 
The authors are indebted to all of the patients and the staff of the participating 
institutions of the Japan Society for Hematopoietic Cell Transplantation, the Japan 
Marrow Donor Program, The Japanese Cord Blood Bank Network and The Japanese 
Society of Pediatric Hematology. The authors would like to thank Ms. Takako Sakai, 
data manager of the Japan Society for Hematopoietic Cell Transplantation Data Registry, 
for their excellent assistance. 
 
Conflict of Interest 
The authors declare no competing financial interests. 
 10 / 14 
 
References 
1. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, et al. A 
Markov decision analysis of allogeneic hematopoietic cell transplantation versus 
chemotherapy in patients with acute myeloid leukemia in first remission. Blood  
Feb 17; 117(7): 2113-2120. 
 
2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The 
importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 
patients entered into the MRC AML 10 trial. The Medical Research Council Adult 
and Children's Leukaemia Working Parties. Blood 1998 Oct 1; 92(7): 2322-2333. 
 
3. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et 
al. Karyotypic analysis predicts outcome of preremission and postremission therapy 
in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative 
Oncology Group Study. Blood 2000 Dec 15; 96(13): 4075-4083. 
 
4. van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge 
RM, et al. Allogeneic stem cell transplantation for patients with acute myeloid 
leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 
abnormalities. Haematologica 2005 Oct; 90(10): 1339-1345. 
 
5. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, 
et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the 
 11 / 14 
 
need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid 
malignancies. Leukemia 2006 Jul; 20(7): 1295-1297. 
 
6. Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Maeda T, et al. Allogeneic 
hematopoietic stem cell transplantation for acute myeloid leukemia with 
t(6;9)(p23;q34) dramatically improves the patient prognosis: A matched-pair 
analysis. Leukemia 2011. 
 
7. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide 
for clinicians. Bone Marrow Transplant 2007 Aug; 40(4): 381-387. 
 
8. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities 
in the presence of competing risks: new representations of old estimators. Stat Med 
1999 Mar 30; 18(6): 695-706. 
 
9. Garcon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C, et al. DEK-CAN 
molecular monitoring of myeloid malignancies could aid therapeutic stratification. 
Leukemia 2005 Aug; 19(8): 1338-1344. 
 
10. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. 
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 
years) with acute myeloid leukemia and normal cytogenetics: a study of the AML 
Study Group Ulm. Blood 2002 Dec 15; 100(13): 4372-4380. 
 
 12 / 14 
 
11. Beran M, Luthra R, Kantarjian H, Estey E. FLT3 mutation and response to intensive 
chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 
2004 Jun; 28(6): 547-550. 
 
12. Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, et 
al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. 
Clin Cancer Res 2005 Feb 15; 11(4): 1416-1424. 
 
13. Oyarzo MP, Lin P, Glassman A, Bueso-Ramos CE, Luthra R, Medeiros LJ. Acute 
myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high 
frequency of flt3 gene mutations. Am J Clin Pathol 2004 Sep; 122(3): 348-358. 
 
14. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis 
of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: 
association with FAB subtypes and identification of subgroups with poor prognosis. 
Blood 2002 Jun 15; 99(12): 4326-4335. 
 
15.Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, et al. 
Detailed analysis of FLT3 expression levels in acute myeloid leukemia. 
Haematologica 2005 Dec; 90(12): 1617-1625. 
 
16. Koh Y, Park J, Ahn KS, Kim I, Bang SM, Lee JH, et al. Different clinical 
importance of FLT3 internal tandem duplications in AML according to FAB 
 13 / 14 
 
classification: possible existence of distinct leukemogenesis involving monocyte 
differentiation pathway. Ann Hematol 2009 Nov; 88(11): 1089-1097. 
 
17. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008 Jul; 
45(3 Suppl 2): S17-21. 
 
18. Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Bohmer FD, et al. A 
novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in 
AML. Blood 2009 Apr 23; 113(17): 4063-4073. 
 
 14 / 14 
 
Figure legends 
Figure 1. The probabilities of OS in the patients with the t(6;9)(p23;q34) abnormality. A. 
The OS of the patients stratified by age at HSCT. Solid line, pediatric patients younger 
that 14 years; dotted line, adult patients older than 15 years. B. The OS of the patients 
stratified by the disease status at HSCT. Bold line, all patients; Solid line, patients in 
CR; dotted line, patients in non-CR. 
 
Figure 2. The cumulative incidence of events after allo-HSCT stratified by the disease 
status at the time of HSCT. A. The cumulative incidence of relapse of the patients. B. 
The cumulative incidence of NRM of the patients. Solid line, patients in CR; dotted line, 
patients in non-CR. 
  
Figure 3. The probability of OS of the patients grouped according to the FAB 
classification and the disease status at HSCT. Solid line, FAB-M2 patients in CR; 
dashed line, non-FAB-M2 patients in CR; dotted line, FAB-M2 patients in non-CR; 
chain line, non-FAB-M2 in non-CR. 
























































































not in CR (n=17)
Non-M2 patients in CR (n=13)
Non-M2 patients,
not in CR (n=10)
Table 1. Characteristics of patients with t(6;9)(p23;q34).
Children (n=7) Adult (n=57)
Age, median (range) 9 (6-14) 35 (17-58)
Gender,
male / female
1 / 6 34 / 23







5 / 2 29 / 28
HLA disparity** 0 2 24
1 2 5
2 0 10
Graft source BM 3 32
PBSC 2 12
CB 2 13
*: Data not available in 2 adult patients.
**: Data not available in 3 pediatric patients and 18 adult patients.
Abbreviations: BM, bone marrow; CB, cord blood; CR, complete 
remission; HSCT, hematopoietic stem cell transplantation; PBSC, 
peripheral blood stem cells.
Table 2. Prognostic factors affecting overall survival of adult patients with t(6;9)(p23;q34).
HR 95% CI P
CR 1
non-CR 2.54 1.17-5.51 <0.02
M2 1






Abbreviations: BM, bone marrow; CB, cord blood; CI, confidence interval; CR, complete 
remission; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; NA, not 
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